Business
Merck wins Chinese obesity drug in nearly $2 billion deal
Merck will win an exclusive global license to Chinese drugmaker Hansoh’s HS-10535, an investigational oral drug targeting the GLP-1 receptor. Read more
Merck will win an exclusive global license to Chinese drugmaker Hansoh’s HS-10535, an investigational oral drug targeting the GLP-1 receptor. Read more